Abstract
The extent of clearance of leukemic cells from the blood or bone marrow during the early phase of therapy is an independent prognostic factor in acute lymphoblastic leukemia (ALL). Several methods are available to measure the minimal residual disease (MRD) remaining after initial intensive chemotherapy. The most promising are flow cytometric detection of aberrant immunophenotypes and polymerase chain reaction analysis of clonal antigen-receptor gene rearrangements. When applied together, these techniques enable one to monitor MRD in virtually all cases of ALL. Patients who achieve an ‘immunologic’ or ‘molecular’ remission (ie leukemic involvement of <0.01% of nucleated bone marrow cells at the end of remission induction therapy) are predicted to have a better clinical outcome than patients whose remission is defined solely by morphologic criteria. in studies to date, patients with mrd at a level of 10−2 or more at the end of induction have fared almost as poorly as those with ⩾5% blast cells in the bone marrow (ie induction failures). Sequential monitoring of MRD can improve the clinical utility of risk assessment still further. Additional studies are needed to determine the critical levels of MRD at various times of treatment and whether therapeutic intervention based on MRD findings can improve clinical outcome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Reaman GH, Sather HN, Steinherz PG, Trigg ME, Tubergen DG, Uckun FM . Early response to therapy and outcome in childhood acute lymphoblastic leukemia. A review Cancer 1997 80 1717–1726
Lilleyman JS . Clincial importance of speed of response to therapy in childhood lymphoblastic leukaemia Leuk Lymphoma 1998 31 501–506
Silverman LB, Gelber RD, Young ML, Dalton VK, Barr RD, Sallan SE . Induction failure in acute lymphoblastic leukemia of childhood Cancer 1999 85 1395–1404
Campana D, Pui C-H . Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance Blood 1995 85 1416–1434
Foroni L, Harrison CJ, Hoffbrand AV, Potter MN . Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis Br J Haematol 1999 105 7–24
Campana D, Coustan-Smith E . Detection of minimal residual disease in acute leukemia by flow cytometry Cytometry 1999 38 139–152
Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, Rubnitz JE, Rivera GK, Sandlund JT, Pui C-H, Campana D . Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia Lancet 1998 351 550–554
van Dongen JJM, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig W-D, Basso G, de Bruijn MAC, Gazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WCJ, Riehm H, Bartram CR . Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 1998 352 1731–1738
Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia New Engl J Med 1998 339 591–598
Pui C-H, Evans WE . Acute lymphoblastic leukemia New Engl J Med 1998 339 605–615
Neale GAM, Coustan-Smith E, Pan Q, Chen X, Gruhn B, Stow P, Behm FG, Pui C-H, Campana D . Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia Leukemia 1999 13 1221–1226
Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF . Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia New Engl J Med 1997 336 317–323
Pongers-Willemse MJ, Verhagen OJHM, Tibbe GJM, Wijkhuijs AJ, de Haas V, Roovers E, van der Schoot CE, van Dongen JJ . Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes Leukemia 1998 12 2006–2014
Coustan-Smith E, Behm FG, Sancho J, Boyett JM, Hancock ML, Rivera GK, Rubnitz JE, Sandlund JT, Pui C-H, Campana D . Sequential monitoring of minimal residual disease in childhood acute lymphoblastic leukemia Blood 1999 94 (Suppl. 1) 626a
Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM, Gaynon PS . Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy New Engl J Med 1998 338 1663–1671
Chen J-S, Coustan-Smith E, Suzuki T, Neale GA, Pui C-H, Campana D . Identification of novel leukemia markers by comparative analysis of gene expression with DNA microarrays Blood 1999 94 (Suppl. 1) 657a
Acknowledgements
This work was supported by grants CA 60419, CA 21765, and CA 20180 from the National Cancer Institute, by a Center of Excellence grant from the State of Tennessee, and by the American Lebanese Syrian Associated Charities (ALSAC).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pui, CH., Campana, D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 14, 783–785 (2000). https://doi.org/10.1038/sj.leu.2401780
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401780
Keywords
This article is cited by
-
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
Leukemia (2007)
-
Diagnostic pathways in acute leukemias: a proposal for a multimodal approach
Annals of Hematology (2007)
-
The Seventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Palermo, Italy, January 29–30, 2005
Leukemia (2005)
-
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse
Leukemia (2004)
-
Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia
Leukemia (2004)